Dr Robert Weinkove is Clinical Director at the Malaghan Institute of Medical Research (MIMR), and a Consultant Haematologist at Health New Zealand. After studying natural sciences and clinical medicine at the University of Cambridge and Kings College London, he trained in clinical haematology in London and in Hannover, and undertook a PhD in immunology at the University of Otago.

Dr Weinkove leads a clinical and translational chimeric antigen receptor (CAR) T-cell programme at the Malaghan Institute. He was Principal Investigator of ENABLE-1, a phase 1 first-in-human trial of a third-generation CAR T-cell therapy for B-cell lymphomas, and oversees ENABLE-2, a multicentre phase 2 trial. Dr Weinkove provides clinical oversight for GMP-grade lentiviral vector and CAR T-cell manufacture at BioOra Limited. Dr Weinkove is an active member of the Australasian Leukaemia & Lymphoma Group and contributes to clinical trials and Australasian guideline development in the fields of B-cell malignancies and prevention of infection for immunocompromised patients.